<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2BE96AE1-6B7D-40FE-BB8E-09B1F06DA635"><gtr:id>2BE96AE1-6B7D-40FE-BB8E-09B1F06DA635</gtr:id><gtr:firstName>Peter M</gtr:firstName><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F2E33302-3E45-4D83-9830-080F0A371A82"><gtr:id>F2E33302-3E45-4D83-9830-080F0A371A82</gtr:id><gtr:firstName>Annette</gtr:firstName><gtr:otherNames>I</gtr:otherNames><gtr:surname>Burgess</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601325"><gtr:id>D8E4EDFA-F0BF-4577-9BC2-4B8636DA1432</gtr:id><gtr:title>Association of plasma factor XIIa with risk of ischaemic stroke</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601325</gtr:grantReference><gtr:abstractText>In order to prevent strokes and heart attacks most effectively, doctors need as much information as possible about which patients are at highest risk. This project will reliably determine whether measurement of a new risk factor (factor XIIa) will help doctors to do this. Since we have already shown that it is possible to alter factor XIIa levels we might then be able to develop drugs to treat patients with abnormal levels in order to reduce their risk of stroke and heart disease. The same process of identifying a risk factor and then altering the level was the basis of the development the treatments that we now have for high blood pressure and high cholesterol.</gtr:abstractText><gtr:technicalSummary>Background: The lack of reliable data on risk factors for stroke, particularly in secondary prevention, has been highlighted repeatedly. We have developed risk models to predict recurrent stroke in several clinical situations, but greater prognostic power is required if reliable predictions are to be obtained for individuals. Thrombosis is a key pathological process in TIA, ischaemic stroke and acute coronary syndromes and several coagulation proteins are risk factors for development of atherosclerosis and/or acute arterial thrombotic events, particularly in the young, but there have been no large studies in unselected (predominantly elderly) patients with TIA or stroke. Our pilot studies in the Oxford Vascular Study indicate that of a panel of markers of platelet/endothelial cell activation, thrombosis and platelet function, only activated FXII (FXIIa) has the potential to be a clinically useful prognostic marker 

Aim: To fully document the prognostic value of FXIIa in 2000 patients with TIA and stroke and to compare levels (stratified by clinical and aetiological subtype) with those in 1000 population controls without vascular disease. 

Methods: Two forms of FXIIa will be measured at presentation and at 1 month follow-up in 2000 well-phenotyped patients with acute TIA and stroke in the Oxford Vascular Study. FXIIa levels will be related to risk of recurrent stroke and other vascular events during follow-up. Spouse or friend population controls will be selected from the Oxford Vascular Study Control Cohort in order to also perform a case-control study to help determine whether FXIIa levels are likely to also be of prognostic value in the general population primary prevention setting.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>345737</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>02057B88-DDA7-40C1-91EF-99FB68667CC5</gtr:id><gtr:title>Fabry disease in unselected patients with TIA or stroke: population-based study.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/203c789047db64e75b4a826eb6c31ad3"><gtr:id>203c789047db64e75b4a826eb6c31ad3</gtr:id><gtr:otherNames>Marquardt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>pm_540e144e1444debc2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DDEE029-7309-457E-8D4A-56C35AFA8760</gtr:id><gtr:title>Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ff905ca396cdd019b10c080a5d07bcb"><gtr:id>4ff905ca396cdd019b10c080a5d07bcb</gtr:id><gtr:otherNames>Traylor M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_540e144e144a93158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52C6DA3-A088-40DC-9064-5079EEAAA8B2</gtr:id><gtr:title>Mitochondrial DNA haplogroups and risk of transient ischaemic attack and ischaemic stroke: a genetic association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1f4b7c0cf2741f213eff19fe22e37f"><gtr:id>fe1f4b7c0cf2741f213eff19fe22e37f</gtr:id><gtr:otherNames>Chinnery PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_540e143e143dc5eda</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601325</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>